



Molecular Localization of Epstein Barr Virus and Rb Tumor Suppressor Gene Expression in Tissues from Prostatic Adenocarcinoma and Benign Prostatic Hyperplasia

Saad Hasan Mohammed Ali ¹

Shakir H. Mohammed Al-Alwany ²

¹ College of Medicine / University of Baghdad

² College of Science / University of Babylon

Abstract: Epstein- Barr virus (EBV) is a ubiquitous in that infecting more than 90% of adult population worldwide. Recently, EBV has been linked to the development of variety of human malignancies including prostate tissues that range from benign prostatic hyperplasia (BPH) to prostatic adenocarcinoma (PAC). Somatic point mutations in Rb gene have been detected in prostate cancer and are involved in progression steps of prostate carcinogenesis. To analyze the distribution and impact of concordant Rb expression and latent EBV infection on a group of prostate adenocarcinoma and benign prostatic hyperplasia. Seventy- two formalin-fixed, paraffin- embedded prostatic tissues were obtained in this study; 40 biopsies from prostatic carcinoma and 20 from benign prostate hyperplasia as well as 12 apparently normal prostatic autopsies control group. Detection of EBV-EBERs was done by ultra-sensitive version of *in situ* hybridization method where as immunohistochemistry detection system was used to demonstrate the expression of *Rb* gene. Detection of EBV-EBERs -ISH reactions in tissues with PAC was observed in 19 out of 40 (47.5%), while in the tissues from BPH was detected in 10% (2 out of 20). No EBV-EBERs positive – ISH reaction was detected in healthy prostate tissues in the control group. The differences between the percentages of EBERs detection in tissues PAC and each of BPH & control groups were statistically highly significant ($p < 0.01$). Positive Rb immune histo chemical (IHC) reactions were observed in 19 PAC cases (47.5%) and in 2 BPH cases (10%). Our results indicate that the EBV might contribute to the development of subset of prostate tumors. In addition, the significant percentage of expression of possible Rb gene as well as EBV in prostate adenocarcinoma could indicate for an important role of these molecular and viral factors in prostatic carcinogenesis.

Key word: EBV; prostate adenocarcinoma, benign prostatic hyperplasia, in situ hybridization.

Author e-mail (Shak_immuno@yahoo.com)

التموضع الجزيئي للتعبير الجيني لراشح الالبشتاين بار والجين الكابت السرطاني Rb في أنسجة البروستات السرطانية والحميدة

سعد حسن محمد علي¹ شاكرا العلواني²

¹كلية الطب- جامعة بغداد

²كلية العلوم- جامعة بابل

الخلاصة: ايبشتاين- بار فيروس (EBV) فايروس يتواجد في كل مكان و يصيب أكثر من 90% من السكان البالغين في جميع أنحاء العالم. في الآونة الأخيرة تم ربط EBV في تطور مجموعة متنوعة من الأورام الخبيثة للإنسان بما في ذلك أنسجة البروستات التي تتراوح من تضخم البروستات الحميد (BPH) الى سرطان غدية البروستات الخبيث (PAC). تم الكشف عن الطفرات النقطية الجسمية في جينات الريتينوبلاستوما RB في سرطان البروستات والتي تشارك في خطوات تطور سرطان البروستات. الغرض من الدراسة عن الكشف عن علاقة ايبشتاين- بار فيروس (EBV) للإصابات الكامنة وتأثير تعبير جين الريتينوبلاستوما RB على مجموعة من مرضى سرطانات غدية البروستات وتضخم البروستات الحميد. تم الحصول على اثنين وسبعين عينة مريض لأنسجة البروستات المثبتة بالفورمالين، والتي مثلت عينات الدراسة وكالاتي: اربعون خزعة من سرطان غدية البروستات وعشرون خزعة من تضخم البروستات الحميد فيما مثلت اثنا عشر خزعة من أنسجة البروستات للأشخاص السليمين كمجموعة سيطرة. تم الكشف عن ايبشتاين- بار فيروس (EBV) بوساطة طريقة التهجين الموقعي ذات الحساسية العالية، بينما تم استخدام تقنية الفحص الكيميائي المناعي النسجي للتدليل على تعبير جينات الريتينوبلاستوما RB. اظهرت نتائج الكشف عن ايبشتاين- بار فيروس (EBV) بوساطة طريقة التهجين الموقعي ذات الحساسية العالية (ISH) في أنسجة سرطان غدية البروستات نسبة 47.5% (19 من 40 عينه)، بينما في أنسجة بروستات الورم الحميد (BPH) كانت نسبة الإصابة 10% (2 من 20 عينه). لا توجد نتائج موجبة للإصابة ب ايبشتاين- بار فيروس (EBV) في أنسجة البروستات للأشخاص السليمين المستخدمين كمجموعة سيطرة. اظهر التحليل الاحصائي للفروق بين النسب المؤوية للكشف عن ايبشتاين- بار فيروس (EBV) في أنسجة سرطان غدية البروستات PAC وكل من وتضخم البروستات الحميد BPH ومجموعة السيطرة فرقا معنويا عاليا عند ($P < 0.01$). كانت نتائج الفحص الكيميائي المناعي النسجي لسرطان غدية البروستات ايجابية بنسبة 47.5% (19 من 40 عينه) وفي تضخم البروستات الحميد بنسبة 10% (2 من 20 عينه) بينما في مجموعة السيطرة كانت النتائج سلبية.

نتائج الدراسة الحالية تشير إلى أن EBV قد تسهم في تطوير فرعية من أورام البروستات. وبالإضافة إلى ذلك، يمكن للنسبة الكبيرة من التعبير الجيني لـ RB لهما دوران مهمان كعوامل فايروسية وجزيئية في تسرطن البروستات.

Introduction

Most common neoplasms of the male genital tract involve the prostate gland (16). Prostate cancer is the fifth common cancer world-wide and second in cancer mortality exceeded only by lung cancer (4, 19).

Viral factors are the most important class of infectious agents associated with human cancers (15). It was estimated that 17-20% of all worldwide incidence of cancers are attributable to a viral etiology (5).

EBV is a typical virus consisting of a core containing a linear, double stranded DNA; an icosahedral capsid, approximately 120-200 nm in diameter, containing 162 capsomeres; an amorphous material that surrounded the capsid, (tegument) and an envelope containing viral glycoprotein spikes on its surface (20). Sequence analysis has defined two strains of EBV: type I and type II (alternatively named EBV A and B) which differ at the domains that encode EBV latent proteins, namely EBERs, and the nuclear antigens EBNA-LP, 1, 2, 3A, 3B and 3C in latently infected cell (6).

EBV has been classified as a group 1 carcinogen associated with a variety of lymphoid and epithelial malignancies by the international agency for research of cancer {IARC} (9). Evidence of EBV being a monogenic virus is driven from its ability to infect and transform normal human B cells in vitro, resulting in immortalization of these cells and

leading to continuous growth of lymphoblastoid cell lines. Moreover, EBV can transform human squamous epithelial cells in vitro. The virus is involved in the development of several human cancers such as nasopharyngeal carcinoma and various lymphomas (21).

The small untranslated RNAs (EBER-1 and -2) are accumulated at high levels during all forms of latency and regulate apoptosis through different mechanisms. EBER-1 interacts with the interferon-inducible protein kinase R (PKR), and inhibits its activation by double-stranded RNAs, protecting infected cells from INF-induced apoptosis (17).

EBV encoded small RNAs have however a more prominent role in EBV-mediated growth transformation, as viruses lacking the coding sequence for this RNA were significantly less efficient in generating lymphoblastoid cell lines (LCLs) in vitro, and the cell lines generated proliferation at much lower rates, due to reduced autocrine IL-6 production (23). These observations have been extended to epithelial cell lines, where EBERs induced the expression of growth factors that promote cell survival (11).

The EBV latent proteins expression contribute to most, if not all, of the transforming and immortalizing properties of this prototype DNA oncogenic viral agent. In addition to EBNA1 and the EBERs, human cancer cells, that are latently infected with this virus express the

most powerful oncogenic proteins, LMP-1 and LMP- 2(A and B) (17).

Besides chromosomal loss and mutation , there are various other mechanisms for Rb inactivation. Also, Rb can be inactivated in tumors by the loss of one allele and hypermethylation of the other alleles (8). Interestingly, a recent survey of Rb status in metastatic breast cancer revealed two cases with duplication of the entire gene (2). This may be related to a phenomena observed in colorectal carcinoma, where high expression of pRb was shown ,paradoxically ,to protect from E2F-induced apoptosis (2,3). In addition ,expression of constitutively active phosph-mutant Rb transgenes in mouse mammary epithelium induces adenocarcinoma(16). Thus, both activation and inactivation of protein Retinoblastoma can be oncogenic in the mammary gland (12). Rb inactivation was observed to increase the proliferative potential of the cells which was associated with overexpression of cyclin dependent kinase (7). The deregulation of the Rb pathway is the primary function of each of the DNA tumor virus oncoproteins that promote cellular proliferation, this includes the adenovirus E1 A protein, polyoma virus ,SV40 T antigen and HPV E7 protein(13). Rb is functionally inactivated in 25-30% of prostate cancers; furthermore, Rb loss is correlated with increasing tumor stage and grade. The clinical consequences of Rb loss are unknown. It was shown

previously that Rb loss results in a castrate resistant phenotype. The hypothesized that Rb loss would down regulate the G1-S cell cycle arrest normally induced by irradiation, inhibit DNA repair, and subsequently sensitize cells to mitotic catastrophe (13).

Materials and methods

The study was designed as a retrospective one. It has recruited 72 selected formalin fixed, paraffin embedded prostatic tissue blocks among them; 40 tissue biopsies from prostatic carcinoma with different grades and 20 benign prostate hyperplastic tissue blocks as well as 12 apparently normal prostate tissue autopsies which were collected from the archives of Forensic Medicine Institute / Baghdad and used as prostate healthy tissues control groups. The diagnosis of these tissue blocks were based on their accompanied records. A consultant pathologist reexamined all these cases to further confirm the diagnosis following trimming process of these tissue blocks.

One section was mounted on ordinary glass slide and stained with hematoxyline and eosin, while another slide was mounted on charged slide to be used for ISH for detection of EBV .The detection of EBV-EBERs by ISH kit (Zyto Vision GmbH. Fischkai, Bremerhaven. Germany) mounted with permanent mounting medium (DPX).

Immunohistochemistry / Detection system (US Biological Inc . USA) .

Chi –square test was used to detect the significance of variables in our study. All the statistical analysis was done by SPSS program (Version–17) & P value was considered significant when $p < 0.05$.

Results

The distribution of Gleason’s grading of prostate carcinoma according to the ISH results for EBV-EBERs detection.

The EBV-EBERs positive results of ISH were detected in 50%

(8 out of 16) of tissues with prostatic cancers showing Gleason’s grade (8-10) (poorly differentiated grade), followed by the tissues showing Gleason’s grade (5-7) (moderate differentiated grade) (i.e. 6 out of 13) where it comprised 46.2% of the total number of this grade , and lastly by tissues with Gleason’s grade (2-4) (well differentiated grade) where it constituted 45.5% of total number of this grade (i.e. 5 out of 11).

Statistically, the distribution of ISH results for detection of EBV-EBERs according to the Gleason’s grading of prostate carcinoma shows non-significant differences ($P > 0,05$) (table 1).

Table (1): Distribution of ISH results for EBV-EBERs according to Gleason's grading of prostatic carcinoma.

Gleason's Grade		EBV-EBERS-ISH		Total	Comparison of Significance	
		Positive ISH	Negative ISH		P-value	
2-4	N	5	6	11	0.15	
	%	45.5	54.5	100		
5-7	N	6	7	13		
	%	46.2	53.8	100		
8-10	N	8	8	16		
	%	50	50	100		
Total	N	19	21	40		
	%	47.5	52.5	100		

*Non Significant ($P > 0.05$).

*The difference in signal scoring results for detection of EBV-EBERs-ISH according to the Gleason’s grading of prostate carcinoma shows non-significant differences ($P > 0.05$) [NS] (P Kruskal-Wallis = 0.15).

The Results of EBV- ISH among Study Groups

It was found after application and analysis of (ISH) results of EBV--EBERs in the tissues obtained from patients with prostatic cancer as well as benign prostatic hyperplasia that (19) out of (40) patients with carcinoma of prostate showed positive in situ hybridization reaction where it constituted 47.5% of the total prostatic cancer cases of this study (table 2 and figure 1). In the benign group, 10% has

revealed positive signals, which represented 2 out of 20 cases in this group, whereas none of control group presented with positive signals for EBV-EBERs-ISH test. However , in comparison to the percentage of EBV -EBERs in healthy control group as well as in the group of benign prostatic hyperplasia, the differences between the percentages of EBV-EBERs in prostatic cancers and each of these groups are statistically significant (P value = < 0,001).

Table (2): The distribution of ISH results for EBV – ISH detection according to the Gleason's grading of prostatic carcinoma.

Gleason's Grade		EBV-EBERS-ISH		Total	Comparison of significant	
		Positive ISH	Negative ISH		P-value	
2-4	N	5	6	11	0.658	
	%	45.5	54.5	100		
5-7	N	6	7	13		
	%	46.2	53.8	100		
8-10	N	8	8	16		
	%	50	50	100		
Total	N	19	21	40		
	%	47.5	52.5	100		

*Non Sig.(P>0.05)

The difference in signal scoring of positive reactions for EBV- EBERs between benign prostatic hyperplasia and prostatic cancer groups (healthy controls are not part in this

comparison, since all of them were negative) was statistically highly significant [HS] (P Kruskal-Wallis = 0.001).




Figure (1): In situ hybridization results for EBV-DNA detection in prostate tumors; BCIP/NBT stained and counter stained by nuclear fast red; A. Healthy Prostatic tissues with negative ISH reaction for EBV (10X).B. prostate cancer with positive ISH reaction for EBV-DNA (40X). Co-existence of EBV-EBERS-ISH and Rb –IHC expression in tissues with prostatic cancers.

The percentage of positive Rb-tumor suppressor gene expression that associated with positive EBV-EBERS ISH reaction was constituted (63.2%:12 out of 19 cases) in prostatic cancer group, while the percentage of positive Rb expression was (36.8% :7 out of 19 cases) in prostatic cancerous tissues that showed EBV-EBERS-negative reaction by ISH technique. Also, in BPH the percentage of positive Rb-Tumor suppressor gene expression that showed also positive EBV- EBERS reaction was constituted (10%: 2 out of 20 cases) in prostatic

cancer group, while the percentage of positive Rb expression in prostatic cancerous tissues that showed EBV-EBERS negative reaction was (28.6% : 4 out of 20 cases) (table 3 and figure 2). The statistical analysis showed significant association ($p < 0.05$) on comparing the results (according to score) when group of prostate cancer was compared to control group, but the statistical difference between benign breast tumor and control groups was not significant.

Table (3): Co-localization of EBERs along with Rb gene expression in tissues with prostatic cancers.

Studied groups				EBV- EBERS-ISH		Total
				Positive	Negative	
Prostatic Cancer	Rb IHC Reaction	Positive	N	11	8	19
			%	63.2	36.8	100
		Negative	N	5	16	21
			%	23.8	76.2	100
		Total	N	16	24	40
			%	40	60	100
Benign Prostatic Hyperplasia	Rb IHC Reaction	Positive	N	2	18	20
			%	10	90	100
		Negative	N	4	14	18
			%	28.6	71.4	100
		Total	N	6	14	20
			%	30	70	100
The Control	Rb IHC Reaction	Positive	N	0	0	0
			%	0	0	0
		Negative	N	0	12	12
			%	0	100	100
		Total	N	0	12	12
			%	0	100	100




Figure (2): Immunohistochemical results for Rb expression detection in prostate tumor; DAB chromogen stained (brown) and counter stained by Mayer's hematoxyline (blue); A. Prostate cancer with positive IHC reaction (100X). B. Benign prostatic hyperplasia with negative IHC reaction (10X).

Discussion

Significantly high percentage of EBERs detection in PAC group (47.5%) was observed on comparison to BPH and control groups. These results are consistent to those reported by (10) who identified EBV in 37% (7 out of 18 cases) of prostate adenocarcinoma in US males by immunohistochemistry and PCR techniques and to those obtained by (18) who identified EBV in 40% (4 out of 10 cases) of malignant prostate tissue in Australia. However, (2) identified EBV in 8.8% (31 out of 352 cases) in benign and malignant prostate tissues in Sweden while (22) identified EBV in 8% (16 out of 200 cases) of malignant prostate tissues. The small sample size enrolled in the studied groups has compromised the statistical power of this study to detect the effects of these factors under consideration. In addition, the lack of detailed clinical information attached to those prostate tissue samples that were included in this study has also deprived the present study to reach to a solid impression for the real role of those mixed viral infections in prostate carcinogenesis and in turn raised a suggestion to compel an integrate team-work study, at molecular and virological levels to elucidate the role of these factors and many other agents in prostate

carcinogenesis in this country. Also in the future, it will be interesting to design experimental studies to understand the synergistic effect of HPV with EBV and /or HSV mixed infections in prostatic carcinogenesis.

The reason for EBV to exert its oncogenic influences in a particular patients is unknown but is probably associated with co-factors. The findings in the research by (24) have supported hypothesis that the prostate is a habitat for multiple viral and other infectious agents ,some of which have oncogenic potential. In addition ,a study has found that EBV infection may have related to the initial occurrence or further development prostate carcinoma. It is possible that EBV exerts its oncogenic influences in concert with co-factors including a possible collaboration with EBV (18).

Among the examined tissues with Gleason's grades 6-8 ,1-5 ,and 9-10 that were collected from patients with prostatic cancer, 35.7% , 40.0% and 46.2% of them respectively have showed positive – in situ hybridization reactions for EBV-EBERs whereas the rest of the evaluated tissues denied to show any reaction for such viral EBERs. It is noteworthy in this study that an increasing trend of association of EBV infection to accompany the deterioration in the histopathological features of the

examined prostatic cancer tissues, that is an increasing percentages of detection of EBV EBERS with the advancing of Gleason's grading of cancerous tissues of this study. This could also means, in turn, that there are an additional possible effects of EBV infection, along with other factors, in deterioration of the histopathology of prostatic cancerous tissues obtained from those Iraqi studied patients.

Structural alterations in the entire coding regions (exons 1 to 27) of the retinoblastoma (Rb) gene in primary human prostate cancers were investigated, using polymerase chain reaction and single strand conformational polymorphism analysis of RNA. Of 25 samples obtained from patients, four (16.4%) were found to have Rb alterations. DNA sequencing of the PCR products revealed point mutations resulting in single amino-acid substitutions of exons 6 and 19 in two cases, and base deletions of exons 8 and 17 in two cases(14). Two of four cases with Rb mutations were moderately differentiated localized tumors and other two with Rb mutations were poorly differentiated tumors with metastases. Our results could suggest that Rb gene mutation is involved in progression steps of prostate carcinogenesis.

EBV encodes six nuclear proteins, designated EBNA 1-6. The EBNA-5 protein of EBV is also able to bind RB in vitro. In addition Rb can interact with several cellular proteins, including the transcription factor E2F (13). (12) found a striking co-localization between the EBNA-5 (alternatively designated EBNA-LP)and Rb proteins in the lymphoblastoid cell line The researchers.(13) have found the COOH- terminal region of EBNA-5 is not required for complex formation with Rb, forms a complex with E2F during S phase. The latter complex contains cyclin A and cdk2 as well. The Rb has been shown to directly repress c-myc promoter activity in keratinocytes through an element upstream of the P1 transcription initiation site in the c-myc promoter (12).

Conclusions

The high percentage of EBV-associated PAC and BPH in our results might indicate for the oncogenic potential of EBV in these cases as well as pointing for its crucial role in development, transformation and /or progression of a subset of prostate cancers and benign prostatic hyperplasia.

References

1. Bergh J, Marklund I, Gustavsson C, Wiklund F, Grönberg H, Allard A, Alexeyev O, and Elgh F. (2007) No link between viral findings in the prostate and subsequent cancer development. *Br J Cancer*;96:137–139.
2. Berge E, Thompson C, and Messersmith W. (2011) Development of novel targeted agents in the treatment of metastatic colorectal cancer. *J Clin Colorectal Cancer*. 10(4) : 266-278.
3. Bernard R. (2008) Reaction to American Society of Clinical Oncology 2007 update of recommendations for the use of tumor markers in breast cancer. *J. Clin Oncol*. 26(12):2057-8.
4. Bray F, Sankila R, Ferlay J, and Parkin DM. (1995) Estimates of cancer incidence and mortality in Europe. *Eur J cancer* 2002;38:99-166. 5- Clifford GM, Smith S, and Aguado - Franceschi S. (2003) Comparison of IIPV type distribution in high-grade cervical lesions and cervical cancer a meta-analysis. *Br J Cancer* 89: 10.
5. Crawford DH. (2000) The virus structure: Epstein- Barr virus. In: principles and practice of clinical virology 99: 117-114.
6. Conner DP, Kay EW, Leader M, Murphy GM, Atkins G J, and Mabruk M J. (2001). A High degree of chromosomal instability at 13q14 in cutaneous squamous cell carcinomas :indication for a role of a tumor suppressor gene other than Rb. *Am. J. of oncology*. 2001; 10 (4): 34 – 9279.
7. Foster SA, Wong DJ, Barrett MT & Galloway DA (1998). Inactivation of p16 in human mammary epithelial cells by CpG island methylation. *Molecular and Cellular Biology* 18: 1793-1801.
8. Gan R, Yin Z, and Leu T. (2003) Cyclosporine A effectively inhibits graft-versus -host disease during development of Epstein-Barr virus-infecting human B-cell lymphoma in SCID mouse. *Cancer Sci* 94:796-801.
9. Grinstein S, Preciado MV, and Gattuso P. (2002) Demonstration of Epstein-Barr virus in carcinomas of various sites. *Cancer Res*;62:4876–8. 1
10. Iwatsuki K, Yamato T, and Tsuji K. (2005) A spectrum of clinical manifestation caused by host immune response against Epstein-Barr virus infections. *Acta Med Okayama* 58:164-80.
11. Jiang Z, Robert J, Jeff C, Liu, Tao D, Tyler R, Philip ED, Sharon W, Jason I, Herschkow, Sean E, Egan, Charles MP and Eldad Z. 2011 (. RB1 and P53 at the crossroad of EMT and Triple – Negative breast cancer. *Cell*.
12. Joseph and Nevins. (2001) The Rb / E2F Pathway and cancer. *Human Molecular Genetics*. ; 10(7):699 – 703. 19-Klas GW. (1993) The Retinoblastoma gene : role in cell cycle control and cell differentiation. *The FASEB Journal*. 7:841-845.
13. Kubota Y, Fujinami K, Uemura H, Dobashi Y, Miyamoto H, Iwasaki Y, Kitamura H, Shuin T. (1995) Retinoblastoma gene mutations in primary human prostate cancer. *Prostate* 27:314-320.
14. Mao C, Hughes JP and Kiviat N. (2003) Clinical findings among young women with genital human papillomavirus infection. *Am J Obstet Gynecol* 188:677.
15. Mc Nicol PJ and Dodd JG. (1990) Detection of human papilloma virus DNA in prostate gland tissue by using the polymerase chain reaction amplification assay. *Clin Microbiol* 28 (3):409-412. 20-
16. Nanbo A, and Takada K. (2002) The role of Epstein-Barr virus-encoded small RNAs (EBERs) in oncogenesis. *Rev Med Virol* 12: 321-326. 20-
17. Noel JW, Wendy KG, Arisha S, Mathe MO, Warick D, and James SG. (2013) Human Papilloma Virus and Epstein Barr-Virus in Prostate Cancer: Koilocytes Indicate Potential Oncogenic Influences of Human Papilloma Virus in Prostate Cancer. *The Prostate*, 73:236-241.
18. Parkin DM, Bray F, Ferlay J, and Pisani P. (2005) Global cancer statistics, 2002. *CA Cancer J Clin* 55: 74- 108.

19. Roizeman R. Herpesviridae; (1991) A brief introduction in virology, 2nd Ed. 1787-1793.
20. Sanjose S, Bosch R, and Schouten T.(2003) Epstein-Barr virus infection and risk of lymphoma: Immunoblot analysis of antibody response against EBV-related proteins in a large series of lymphoma subjects and matched controls. *Int J cancer* 121:1806-1812.
21. Sfanos KS, Sauvageot J, Fedor HL, Dick JD, De Marzo AM, and Isaacs WB.(2008) A molecular analysis of prokaryotic and viral DNA sequences in prostate tissue from patients with prostate cancer indicates the presence of multiple and diverse microorganisms. *Prostate* 68:306–320.
22. Yajima M, Kanada T, and Takada K . (2005) Critical role of Epstein-Barr virus(EBV)- encoded RNA in efficient EBV- induced B- lymphocyte growth transformation. *J Virol* 79:4298-4307. doi:10.1128/JVI.10.10.15703-4307.
23. Zambrano A, Kalantari M, Simoneau A, Jensen JL, and Villarreal LP.(2002) Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. *Prostate*; 53:263–276.